1-Hydroxybenzotriazole → 2-(1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)-N-[4-(4-isobutylphenyl)-1,3-thiazol-2-yl]acetamide
Reaktionsgleichung
[CH3:1][N:2]1[C:7]2=[CH:8][S:9][C:10](C)=[C:6]2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14].[CH2:15]([C:19]1[CH:24]=[CH:23][C:22]([C:25]2[N:26]=[C:27]([NH2:30])[S:28][CH:29]=2)=[CH:21][CH:20]=1)[CH:16]([CH3:18])[CH3:17].CCN=C=NC[CH2:37][CH2:38]N(C)C.Cl.C1C=CC2N([OH:52])N=NC=2C=1>CN(C1C=CN=CC=1)C.ClCCCl>[CH3:1][N:2]1[C:10]2[S:9][CH:8]=[C:7]([CH2:37][C:38]([NH:30][C:27]3[S:28][CH:29]=[C:25]([C:22]4[CH:21]=[CH:20][C:19]([CH2:15][CH:16]([CH3:18])[CH3:17])=[CH:24][CH:23]=4)[N:26]=3)=[O:52])[C:6]=2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14]Komponenten
7
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 2
Versuchsvorschrift
The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.393 mmol) with 4-(4-isobutylphenyl)-1,3-thiazol-2-amine (91 mg, 0.393 mmol) in the presence of EDCI hydrochloride (90 mg, 0.472 mmol), HOBt (16 mg, 0.117 mmol) and DMAP (5 mg, 0.039 mmol) in 1,2 dichloroethane (4 ml) to give 42 mg of the product as a white solid; 1H NMR (300 MHz, CDCl3) δ 0.88 (d, J=6.3 Hz, 6H), 1.83-1.90 (m, 1H), 2.48 (d, J=6.9 Hz, 2H), 3.51 (s, 3H), 3.57 (s, 3H), 4.06 (s, 2H), 6.88 (s, 1H), 7.04 (s, 1H), 7.16 (d, J=7.8 Hz, 2H), 7.72 (d, J=7.8 Hz, 2H), 10.73 (br s, 1H); APCI-MS (m/z) 469.14 (M+H)+.
Quellen und Nachweise
- ORD-Eintrag
- ord-71d729ddfe314b34876b93d080c32a24
- Quelldatensatz
- uspto-grants-2013_08
- Patentnummer
- US08507503B2
Notizen zur Reaktion
Wird geladen…